Navigation Links
Two Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
Date:12/12/2011

e amount of 0.0032% or less of Bcr-Abl compared to Gleevec (32% taking Tasigna 300 mg twice daily and 15% taking Gleevec 400 mg once daily). The ENESTnd study also continued to show that first-line treatment with Tasigna resulted in significantly fewer patients progressing to advanced phase and blast crisis (AP/BC) stages of disease compared to Gleevec, leading to a significantly lower number of CML-related deaths in patients taking Tasigna versus Gleevec (p=0.0356)(2).

"Data from both ENESTnd and ENESTcmr reinforce that patients taking Tasigna have a greater chance of achieving CMR, the deepest level of response measurable today, compared to those taking Gleevec," said Timothy P. Hughes, MD, ENEST study investigator and Clinical Professor at the University of Adelaide, Australia. "We are encouraged by what we saw in ENESTcmr and further follow-up on both trials should help to determine if more patients can reach undetectable levels of CML over time, which could have important implications for determining criteria for future studies on discontinuation of therapy."

CML is a disease in which the body produces cancerous white blood cells. Almost all patients with CML have an abnormality known as the Philadelphia chromosome, which is comprised of a protein called Bcr-Abl that causes malignant white blood cells to proliferate(3). The success of treatment for CML can be measured by a test called real-time quantitative polymerase chain reaction (RQ-PCR). A molecular response means RQ-PCR shows a reduction in Bcr-Abl in the blood; a CMR means no Bcr-Abl is detected(4,5).

"Data from the ENESTnd 36-month update and the ENESTcmr trial at ASH continue to reinforce the benefits of Tasigna over Gleevec, and support the use of Tasigna for adult patients with chronic-phase Ph+ CML," said Herve Hoppenot, President, Novartis Oncology. "We look forward to even more progress in the future as we observe the impact of achieving deep and sustained molecula
'/>"/>

SOURCE Novartis
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
2. Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
3. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
4. Video: Novartis Vaccines and PTA Battle Flu: Public Health Vaccination Initiative Urges Families Lets Fight Flu Together!
5. More Than 200 Abstracts at ASH and SABCS Reveal Potential Compelling Patient Benefits From Novartis Oncology Current and Pipeline Therapies
6. Video: Data on More Than 15 Novartis Oncology Compounds at ASCO Highlight Progress Toward Targeted Therapies for Diverse Tumor Types
7. Juvenile Diabetes Research Foundation, The Genomics Institute of the Novartis Research Foundation Announce Innovative Diabetes Drug Discovery and Development Partnership
8. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
9. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
10. Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
11. Novartis Pharmaceuticals Corporation Prevails in Medicaid Pricing Case Before Alabama Supreme Court
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)...  Thoratec Corporation (NASDAQ: THOR ), a ... save, support and restore failing hearts, said today it ... On Tuesday, December 2, the company will participate ... Conference.  D. Keith Grossman , President and Chief ... beginning at 11:30 a.m., Eastern Standard Time (8:30 a.m., ...
(Date:11/26/2014)...  Perrigo Company plc ("Perrigo") (NYSE: PRGO ... Healthcare Products®," today announced the closing of Perrigo,s previously ... 6,809,210 ordinary shares at a public offering price of ... option to purchase up to an additional 888,157 ordinary ... Inc., as representatives of the several underwriters. ...
(Date:11/26/2014)... WOODLANDS, Texas , Nov. 26, 2014 /PRNewswire/ ... ) today announced the completion of previously announced ... $280.0 million.  After fees and estimated offering expenses, ... from the transactions.  The transactions consisted of: ... of common stock, pursuant to a registration statement ...
Breaking Medicine Technology:Thoratec Announces Presentations At Investor Conferences For December 2014 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 2Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 3Perrigo Company plc Announces The Closing Of Its Registered Public Offering Of Ordinary Shares 4Lexicon Announces Completion Of $280 Million In Financing Transactions 2Lexicon Announces Completion Of $280 Million In Financing Transactions 3
... Multi-Center Phase 1 Trial to Commence -, ... Sheets: ARDC), a company focused on the discovery ... viral,diseases, cancer and inflammatory diseases, today announced that ... status to the,Investigational New Drug (IND) application for ...
... Center of the San Francisco Bay research seeks couples ... ... Reproductive Science Center,of the San Francisco Bay Area, in ... evaluate the safety and effectiveness of,ViaCyte, an investigational product intended ...
Cached Medicine Technology:Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients 2Ardea Biosciences' Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients 3Bay Area Women Sought for Egg Freezing Study 2
(Date:11/27/2014)... children to help with chores while they are home from ... boosts self-esteem, and above all, helps parents maintain a somewhat ... how do you encourage your children to want to help? ... Child Development Journal, there is. The study found that adults’ ... to lend a hand. , The study found that ...
(Date:11/27/2014)... "The uglier, the better," says Dr. Kirk Kimmerling. ... of laughter as we enjoy the ugly sweater contest." ... from scratch. " It was a sight to see. ... ridiculous enough, the Christmas balls were faces of the staff ... in participating this year, it's simple to get in on ...
(Date:11/27/2014)... India (PRWEB) November 27, 2014 Ethane ... company, has announced online reputation management service. ... a comprehensive study about the world of internet marketing ... and Yahoo. , Ethane Web Technologies does not ... it first analyzes the project to reach a conclusion ...
(Date:11/27/2014)... November 27, 2014 Ethane Web Technologies, an ... will provide a 10% Christmas discount on PPC service. The ... The discount offer will begin on 1 December 2014 and ... About this offer, a PPC professional working at Ethane Web ... for small businesses, as this big discount would make the ...
(Date:11/27/2014)... 26, 2014 Lintelus, Inc., an ... focused on increasing audience engagement at Convergence Summit ... software platform includes a multitude of interactive features ... a collaborative, interactive multi-screen environment. Best of all, ... in real time on their own device. , ...
Breaking Medicine News(10 mins):Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 2Health News:Verde Pointe Dental Associates Hosts 2014 Ugly Holiday Sweater Contest 3Health News:Ethane Web Technologies Announces Online Reputation Management Service 2Health News:Ethane Web Technologies Announces 10% Christmas Discount on PPC Service 2Health News:Lintelus Showcases its Feature-Rich Presentation Technology Solution at Convergence Summit’s Annual Event in London 2
... way mothers interact with their babies in the first year ... on. Both a mother,s parenting style and an infant,s temperament ... Lahey and his team from the University of Chicago in ... in Springer,s Journal of Abnormal Child Psychology . , ...
... As part of an initiative to,give back to ... its annual,scientific meetings, the American Society for Therapeutic ... Community - Greater Boston,to raise awareness of cancer ... will join forces with ASTRO by,participating in the ...
... announced today that it has opened a Center for ... Company,s third in the state of,California, one of many ... this location represents the 7th new Center opened in ... According to the National Institute of Health, the ...
... of EP and large untreated patient population to drive ... market, according to Millennium Research Group, ... market will grow significantly over the next five years, ... treatment of cardiac,arrhythmias (a disorder that causes abnormal heart ...
... for Terrorism Preparedness and ... Emergency Response, ... was,selected by the Centers for Disease Control and Prevention (CDC) to ... Emergency Response (COTPER) in Atlanta. This,task order has one base year ...
... N.J., June 23 The American Society of,Transplantation ... the 2008-2009,board of directors. The officers were introduced ... Toronto, Canada, in May., The officers are: ... Medicine; president-elect, Joren C. Madsen, M.D., D.Phil.,Massachusetts General ...
Cached Medicine News:Health News:Mothers' influence is decisive in tots' first year 2Health News:ASTRO, The Wellness Community - Greater Boston Join to Promote Cancer Survivorship 2Health News:CRH Medical Corporation opens Center in San Diego California 2Health News:Chinese Electrophysiology Market to Grow at a CAGR of 20% Over the Next Five Years 2Health News:Lockheed Martin Wins $24 Million IT Contract With CDC 2Health News:The American Society of Transplantation Announces 2008-2009 Board of Directors 2
... PCE PC-Based Exercise ECG Systems offer clinical ... provide advanced database functionality for paperless storage. ... the Welch Allyn PCE Exercise ECG software ... test system. And with its ability to ...
Versatile and Affordable: The Quinton Q-710 ECG system is a versatile and affordable ECG cart that can be configured to meet your specific needs. It can be set on a counter top or mounted on a sturd...
... testing system from Del Mar Reynolds Medical. ... or bicycle ergometer, PC, Cart, isolation transformer ... the same CardioDirect patient interface module that ... ,The system is also available using the ...
... ECT WS 2000 is designed to monitor, store ... provocative tests, (stress-testing). The system can organize the ... provide them for a quick review and printout ... recorded ECG is transmitted via a small portable ...
Medicine Products: